Open AccessClinical Experience with Apatinib and Camrelizumab in Advance Clear Cell Sarcoma: A Retrospective Study
Author(s) -
Jiaqiang Wang,
Shilei Gao,
Yue Yang,
Xu Liu,
Peng Zhang,
Shuping Dong,
Xin Wang,
Weitao Yao
Publication year - 2021
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s337253
Subject(s) - apatinib , medicine , oncology , sarcoma , adverse effect , surgery , chemotherapy , pathology
Advanced clear cell sarcoma (CCS) is a rare subtype of sarcoma with few effective treatments. Evidence shows that apatinib is efficacious and safe for CCS. This study aimed to assess the safety and efficacy of apatinib and/or camrelizumab (a PD-1 inhibitor) in treating advanced CCS.